CN Bio Awarded Innovate UK Grant to Reduce Animal Use in Pharmacokinetic Studies
Grant funding delivered in partnership with the NC3Rs, in support of UK Government roadmap to reduce animal testing by 2030
Project to develop standardized workflow to more accurately predict drug behaviors, reduce animal testing and streamline development of safer, more effective medicines
CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced it has been awarded £180k grant funding from Innovate UK. Delivered in partnership with the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), the funding aims to support new approach methodologies (NAMs) for use in drug development, aligning with the UK Government’s roadmap to reduce dog and non-human primate (NHP) use in pharmacokinetic (PK) studies 35% by 20301.
The grant will enable CN Bio to develop a workflow integrating data generated using its advanced human multi-organ microphysiological systems (MPS) with physiologically-based pharmacokinetic (PBPK) models – providing a more practical, human-relevant alternative to animal-based PK studies.
